Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are proteins implicated in tumor-associated microvascular angiogenesis. Expressions of VEGF and bFGF in various stages of chemical-induced rat bladder carcinogenesis were immunohistochemically investigated. Thirty-two male 6week-old Wistar rats were given drinking water containing 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) for 20 weeks. VEGF and bFGF were not detected in the normal bladder epithelium. In simple hyperplasia, intensive expression of VEGF was observed in a few epithelial cells, and the expression of epithelial VEGF became more pronounced in papillary or nodular (PN) hyperplasia and papilloma. In carcinoma, heterogeneous expression of VEGF was observed in focal tumor cells, intensely expressed in the invading tumor cells. Ultrastructurally, carcinoma cells showed VEGF immunoreactivity in the cytoplasmic matrix and some rough endoplasmic reticulum, and VEGF-positive and -negative carcinoma cells were also clearly defined. High levels of VEGF mRNA were observed in the carcinoma. However, bFGF was not detected in the epithelium throughout the carcinogenesis. Increased microvessel counts appeared at simple hyperplasia and became more pronounced in PN hyperplasia, papilloma, and carcinoma (F-test; P Ͻ 0.05). In the carcinoma, the microvessel counts of the VEGF-expressing tumor areas were significantly higher than that of the non-VEGF-expressing tumor areas (U-test; P Ͻ 0.05). The present study suggests that upregulation of epithelial VEGF may begin at a quite early stage in BBN-induced rat bladder carcinogenesis, but bFGF may not be involved.
Tumor development requires oxygen and nutrients, which are supplied through angiogenesis. Therefore, angiogenic potential is a prerequisite for tumor growth. 9, 12, 28 The potent mitogenic activity of vascular endothelial growth factor (VEGF) for endothelial cells has been characterized and is considered to be comparable to that of basic fibroblast growth factor (bFGF), which is thought to be the most potent mitogen for endothelial cells among many angiogenic factors. 8, 16 VEGF gene expression has been demonstrated in several tumors of the brain, 21 gastrointestinal tract, 4 kidney, 13 breast, 3, 27 ovary, 2,20 glioblasts, 31 and liver. 17 Bladder carcinoma is generally considered to be a hypervascular tumor. 1 Although VEGF mRNA expression in the human bladder carcinoma has been described, 4, 10 the localization of VEGF protein in bladder carcinogenesis has yet to be considered.
The bladder is one of the major target organs of toxic and/or carcinogenic chemicals. 14 N-butyl-N- (4- hydroxybutyl)nitrosamine (BBN) is a potent carcinogen with a selective organotropism for the bladder in several species, including rats. 11 Histogenesis of bladder tumors caused by BBN involves progression through stages from normal to simple hyperplasia, papillary or nodular (PN) hyperplasia, papilloma, and transitional cell carcinoma. 11 In the present study, we investigated the immunoreactivities of VEGF and bFGF proteins and the microvessel counts in BBN-induced rat bladder carcinogenesis. VEGF mRNA expression in tumors was also determined.
Material and Methods

Animals
Thirty-six male 6-week-old Wistar rats (Japan SLC) were housed, four per plastic cage, on hardwood-chip bedding in an environment-controlled room on a 12-hour light/12-hour dark cycle at 22 Ϯ 2 C and 55% Ϯ 5% relative humidity, with a conventional diet (F-1, Funabashi Form). All experimental procedures were conducted following approval of the Animal Care and Use Committee of the Azabu University School of Veterinary Medicine. Guidelines set by the National Institute of Health and the Public Health Service Policy on the Humane Use and Care of Laboratory Animals were followed at all times.
Experimental design
Thirty-two rats were given drinking water containing 0.05% BBN (Tokyo Kasei Kogyo Co.) for 20 weeks, and a control group of four rats was given drinking water without BBN for 20 weeks. Rats were an anesthetized with diethyl ether and euthanatized by decapitation. The bladder was ligated at the neck, inflated by intraluminal injection of 10% phosphate-buffered formalin (1 ml), and excised. After fixation, bladders were divided sagitally, cut into four strips, and routinely processed for hematoxylin and eosin staining. Bladder lesions induced by BBN were classified as previously described. 25
Immunohistochemistry
Immunoperoxidase labeling of VEGF, bFGF, and von Willebrand factor were carried out on 10% phosphate-buffered formalin-fixed 5-m frozen tissue sections stored at Ϫ70 C. Upon thawing, sections were rinsed in phosphate-buffered saline (PBS), treated with 0.3% H 2 O 2 for 10 minutes, and blocked with 10% goat serum in PBS for 20 minutes. Primary antibodies were affinity-purified rabbit polyclonal anti-VEGF (Santa Cruz Biotec., diluted 1 : 200), monoclonal anti-bFGF (Upstate Biochem., diluted 1 : 100), and monoclonal anti-von Willebrand factor (Serotec, diluted 1 : 500). The cross-reactivity for these antibodies to the corresponding rat proteins has been clarified for VEGF, 18 bFGF, 24 and von Willebrand factor. 15 Bound IgG was detected with biotinylated goat anti-rabbit IgG (Vector Laboratories, diluted 1 : 100) and the avidin-biotin-peroxidase complex (ABC) (Vector Laboratories) method with diaminobenzidine (Sigma). Sections were then counterstained with hematoxylin. For a negative control, nonimmunized rabbit serum was substituted for the primary antibody, and for controls of VEGF and bFGF, diluted antibodies were preincubated for 12 hours at 4 C with 10-fold excess of blocking peptide. Electron microscopic immunohistochemical analysis for VEGF was performed according to a standard protocol. 29 
Microvessel count
For the evaluation of microvessel count, a quantitative morphological study was performed as previously described. 30 To study the microvascular counts, all specimens were immunohistochemically stained by von Willebrand factor. Microvessels were defined as von Willebrand factor-positive endothelial cells or endothelial cell aggregates, with or without discrete lumina, which were distinctly separate from nearby microvessels. Microvessel counts were assessed blindly without knowledge of the final pathologic diagnosis using 400ϫ magnification (0.1885 mm 2 /field) by two investigators (TM, HT) simultaneously using a double-headed light microscope. 30 All microvessels, defined as all vessels Ͻ20 m in diameter, were counted. This size range clearly defined all blood capillaries, even those that were somewhat elongated. 12, 28 The entire tumor area of each section was examined. For each set, the mean value, standard deviation, and standard error of the mean were calculated and compared using the Scheffé F-test or the Mann-Whitney U-test by a statistical analysis computer system (Stat View-J 4.5, Abacus Concepts).
Northern blot hybridization
To prepare a DNA probe for rat VEGF, rat VEGF cDNA was inserted in pBluescript SK(ϩ) (by Dr. T. Ogita and Dr. Y. Kir, 4th Department of Internal Medicine, Tokyo University Branch Hospital, Japan). The 592-bp probe was generated by PCR using the pBluescript-containing rat VEGF cDNA as a template. The amplified fragment was purified by agarose gel electrophoresis and labeled with digoxigenin using a DNA labeling kit (Boehringer Mannheim). The effectiveness of digoxigenin labeling was determined by dotblot analysis. Total RNA was isolated from rat bladder tumors and normal control bladders using cold ISOGEN (Nippongene), electrophoresed in 1.2% agarose gel containing 2% formaldehyde, and then transferred onto Hyboundϩ nylon membrane (Amersham). The membrane was baked at 80 C for 2 hours and then prehybridized for 2 hours at 42 C in 5ϫ standard saline citrate (SSC) containing 50% formamide and 0.1% sodium dodecyl sulfute. Hybridization with the digoxigenin-labeled VEGF probe was performed for 16 hours at 42 C in the same solution. The membrane was washed twice with 2ϫ SSC at room temperature and with 0.4ϫ SSC at 65 C. The hybridized digoxigenin-labeled DNA was detected using a CSPD kit (Boehringer Mannheim) and exposed to Fuji RX film (Fujifilm).
Results
Normal bladder epithelium consisted of three or four transitional epithelial cells layers. In BBN-induced rat bladder carcinogenesis, bladder epithelial lesions were classified as simple hyperplasia, PN hyperplasia, papilloma, and transitional cell carcinoma. 25 VEGF and bFGF immunoreactivities were not detected at the normal bladder epithelium. In simple hyperplasia, a few epithelial cells in the basal portion intensely expressed VEGF (Fig. 1) . In PN hyperplasia, many epithelial cells other than superficial umbrella cells showed intense expression of VEGF (Fig. 2) . In papilloma, VEGF was intensely expressed in numerous epithelial cells, including superficial umbrella cells (Fig. 3 ). Bladder carcinoma demonstrated heterogeneity of VEGF expression, with some tumor cells scoring positive and some negative for VEGF, and the invading tumor cells of the carcinoma showed intense expression of VEGF ( Fig. 4 ). However, bFGF was observed in the stromal fibroblasts but not in the epithelium throughout the carcinoma (Fig. 5 ). Ultrastructurally, carcinoma cells showed VEGF immunoreactivity in the cytosol (cytoplasmic matrix) and some rough endoplasmic reticulum (Fig. 6) , and VEGF-positive and -negative carcinoma cells were also clearly defined (Fig. 7) . No specific staining was observed with negative controls. Northern blot hybridization revealed that variable high levels of VEGF mRNA were observed in carcinomas (Fig. 8) .
In rat bladder, increased microvessel counts appeared for simple hyperplasia and pronounced PN hyperplasia, papilloma, and carcinoma (Scheffé F-test; P Ͻ 0.05) ( Table 1 ). The microvessel count in VEGFexpressing tumor areas was significantly higher than that in non-VEGF-expressing tumor areas (Mann-Whitney U-test; P Ͻ 0.05) ( Table 2 ).
Discussion
BBN-induced rat bladder carcinogenesis, although featuring simple and PN hyperplasia, progresses to papilloma and carcinoma. 11 In this study, angiogenesis appeared even in simple hyperplasia as an increase in the number of blood capillaries just beneath the bladder epithelium. Increase of blood capillaries was more pronounced in the PN hyperplasia, papilloma, and carcinoma. bFGF has been reported to show high levels of biological activity for angiogenesis. 26 Recently, a novel angiogenic factor, VEGF, a 46-kd dimeric protein, was purified from the conditioned medium of bovine pituitary follicular satellite cells. 22, 23 VEGF possesses a signal peptide and it is largely free to diffuse in tissues after secretion, 5 but bFGF lacks this peptide. Expression of VEGF is, therefore, thought to directly contribute to the promotion of tumor angiogenesis. 8, 19, 27 However, studies concerning VEGF expression during experimental carcinogenesis have been limited. 6 In this study, epithelial VEGF overexpression was revealed in BBN-induced rat bladder carcinogenesis, whereas bFGF may not be involved.
Although VEGF expression has been demonstrated in several carcinomas 6 and expression in benign tumors has been less carefully studied, it has been reported that benign adenomatous polyps arising in the colon do not express VEGF. 4 However, in simple hyperplasia or bladder preneoplastic lesions in the present study, small numbers of transitional cells showed overexpression of VEGF. These cells may be the source of the primitive neoplastic cells in rat bladder carcinogenesis.
Expression of VEGF became more pronounced following carcinogenesis. In rat bladder carcinoma, tumors consisted of mixtures of areas with high expression of VEGF and areas with slight to no labeling, and microvessel counts in VEGF-expressed areas were significantly higher than those in non-VEGF-expressed areas. Tumor cells may through angiogenesis express high levels of VEGF and thus may be able to establish a blood supply and grow more rapidly. Cellular pleomorphism may also result in the selection of a rapidlygrowing subpopulation, as has been proposed in the multistep model for colonic carcinoma. 7 Although high levels of VEGF mRNA expression in BBN-induced rat bladder carcinoma was observed in this study, we could not determine whether the heterogeneity of tu-mor VEGF expression was linked to VEGF mRNA expression. Elevated expression of VEGF has been reported in ovarian carcinomas, especially at the invading tumor cells. 2 In this study, invading tumor cells also showed intense overexpression of VEGF. These invading subgroups of tumor cells might be a more aggressive phenotype.
The present study provides the first evidence that VEGF may play a key role in the development of angiogenesis in the process of BBN-induced rat bladder carcinogenesis. Upregulation of epithelial VEGF may already begin at an early stage of the carcinogenesis, e.g., simple hyperplasia, and may become more pronounced as the process continues. Further study is required to determine the VEGF mRNA expression levels in each bladder tumor stage and/or grade.
